Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BW-00112 in mixed dyslipidemia
NCT06497127Phase 2Active, not recruiting
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Jun 2026
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of BW-00112 in mixed dyslipidemia, sponsored by Shanghai Argo Biopharmaceutical Co., Ltd.. Started Feb 2024; status: active, not recruiting.
02
Drugs
BW-00112
03
Conditions
mixed dyslipidemia
Beyond the preview
Go deeper on NCT06497127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497127.